



**Development of food-grade nanoemulsions and emulsions
for delivery of omega-3 fatty acids: Opportunities and
obstacles in the food industry**


Journal:	<i>Food & Function</i>
Manuscript ID:	FO-REV-08-2014-000723.R1
Article Type:	Review Article
Date Submitted by the Author:	17-Oct-2014
Complete List of Authors:	Walker, Rebecca; University of Massachusetts, Dept. Food Science Decker, Eric; University of Massachusetts, Dept. Food Science McClements, D.; University of Massachusetts, Department of Food Science

Development of food-grade nanoemulsions and emulsions for delivery of omega-3 fatty acids: Advances and obstacles in the food industry

Walker et al

Journal: Food & Function

Graphical Abstract:



PUFA: Polysaturated fatty acid ROOH: Lipid hydroperoxide RO·: Alkoyl radiacals L·: lipid radical LOO·: lipid radical

Nanoemulsions and emulsions can be used as delivery systems for omega-3 fatty acids into functional food and beverage products.

1 **Development of food-grade nanoemulsions and emulsions for delivery of**
2 **omega-3 fatty acids: Opportunities and obstacles in the food industry**
3

4 **Rebecca Walker^a, Eric A. Decker^{a,b}, David Julian McClements^{a,b*}**

5
6 *^aDepartment of Food Science, University of Massachusetts, Amherst, MA 01003,*
7 *USA*

8
9 *^bDepartment of Biochemistry, Faculty of Science, King Abdulaziz University, P. O.*
10 *Box 80203 Jeddah 21589, Saudi Arabia*

11
12
13
14
15
16 *To whom all correspondence should be sent:

17 Dr. Julian McClements, Professor

18 Department of Food Science

19 University of Massachusetts

20 Amherst, MA 01103

21 Tel: (413) 545-1019; Fax: (413) 545-1262

22 E-mail: mcclements@foodsci.umass.edu

23 **Abstract**

24 Consumption of biologically active amounts of omega-3 fatty acids is linked to
25 improved human health, which has partly been attributed to their important role in brain
26 development and cardiovascular health. Western diets are relatively low in omega-3 fatty
27 acids and many consumers turn to supplements or functional foods to increase their
28 intake of these healthy lipids. Fish oil is one of the most widely used sources of omega-3
29 fatty acid for supplementation and has greater health benefits than plant sources because
30 of its higher concentration of eicosapentaenoic acid (EPA) and docosahexaenoic acid
31 (DHA). The incorporation of omega-3 fatty acids into foods and beverages is often
32 challenging due to their low water-solubility, poor oxidative stability, and variable
33 bioavailability. Nanoemulsions offer a promising way to incorporate omega-3 fatty acids
34 into liquid food systems like beverages, dressing, sauces, and dips. Nanoemulsions are
35 colloidal dispersions that contain small oil droplets ($r < 100$ nm) that may be able to
36 overcome many of the challenges of fortifying foods and beverages with omega-3 fatty
37 acids. The composition and fabrication of nanoemulsions can be optimized to increase
38 the chemical and physical stability of oil droplets, as well as to increase the
39 bioavailability of omega-3 fatty acids.

40 *Keywords:* Omega-3 fatty acids; fish oil; nanoemulsions; functional foods;
41 nutraceuticals

42 1. Introduction

43 EPA and DHA are the long chain polyunsaturated fatty acids (LC-PUFAs) most
44 commonly found in fish oil and are linked to brain development, cardiovascular health,
45 and inflammation¹⁻⁴. Western diets have been reported to be severely lacking in the
46 amount of omega-3 fatty acids (FA) consumed¹⁻⁴. Consumption of sufficient levels of
47 omega-3 FAs have been identified as a way to reduce mortality risks, especially for
48 cardiovascular disease⁵. It is estimated that the mortality risk of low omega-3 intake was
49 responsible for 84,000 deaths in the US in 2005. Low consumption of EPA and DHA is
50 due to numerous factors such as the high cost of fish, dislike of seafood by many
51 consumers, presence of methyl mercury, and low availability in many geographical
52 locations⁶⁻⁸. The low consumption of EPA and DHA mean that fortification of foods
53 may be one of the most effective ways in increase omega-3 intake and improve health.

54 Much of the early research on omega-3 FAs focused on enrichment of foods using
55 alpha-linolenic acid (ALA), however more attention is now being paid to
56 eicosapentaenoic acid (EPA) and docosahexaenoic (DHA). This rise in interest may be
57 a result of the specific recommendation for EPA and DHA intake by the *National*
58 *Academies* and the *Dietary Guidelines for Americans* in 2010 or the FDA's approval of a
59 qualified health claim for foods or supplements that contain EPA and DHA in 2004^{2,9-12}.

60 The food industry is now taking measures to help consumers increase their omega-3
61 FA consumption by introduction of various kinds of functional foods. Functional foods
62 provide health benefits over and above their basic nutritional aspects¹³. Omega-3
63 enriched foods are quite popular, especially beverages, and there are large areas of
64 growth for omega-3 products in countries with both small and large existing omega-3
65 markets¹⁴. At present, there are a number of functional foods enriched with omega-3
66 fatty acids that are on the market, such as milk, eggs, yogurts, breads, and spreads. Some
67 of these products have been naturally enriched through the diet of the chicken or cow
68 they were obtained from, while others have been enriched through the addition of omega-
69 3 fatty acids as bulk oils, emulsions, or powders¹⁴⁻¹⁶. Nevertheless, there are
70 considerable challenges to incorporating omega-3 FAs into many types of functional food
71 products due to their low water-solubility, poor chemical stability, and variable

72 bioavailability. Consequently, there has been growing interest in the development of
73 appropriate delivery systems to encapsulate, protect, and release omega-3 fatty acids.

74 Nanoemulsions have great potential for overcoming the challenges associated with
75 developing omega-3 enriched food and beverage products. They can be used to
76 encapsulate oils and increase their water-dispersibility¹⁷. They can be designed to have
77 good kinetic stability and high optical clarity, which is important for application in many
78 food and beverage products¹⁸. They can also be designed to increase the oral
79 bioavailability of encapsulated lipophilic components^{19,20}. Despite these advantages,
80 nanoemulsion-based delivery systems must still be carefully designed to ensure good
81 physical and chemical stability, and high bioavailability. The purpose of this article is to
82 highlight the potential of nanoemulsions for the encapsulation, protection and release of
83 omega-3 fatty acids. These delivery systems could be used in the food industry to fortify
84 foods and beverages with these bioactive lipids, or they could be used in the supplement
85 or pharmaceutical industry to increase the bioactivity of therapeutic omega-3 fatty acid
86 formulations.

87 **2. Omega-3 fatty acids**

88 **2.1. Chemistry and health benefits**

89 Fat consumption is necessary for human development, health, and longevity²¹.
90 There are two fatty acids that have been identified as being essential in the human diet:
91 linoleic acid (LA) (18:2 n-6) and alpha-linolenic acid (ALA) (18:3 n-3), which are also
92 known as omega-6 and omega-3 FAs, respectively. These substances are part of a lipid
93 group collectively known as long chain polyunsaturated fatty acids. These fatty acids are
94 considered essential because they cannot be synthesized by the human body as a result of
95 the lack of enzymes that can form double bonds beyond the Δ^9 carbon²¹. After
96 consumption, the essential fatty acids can then be converted in the human body by
97 desaturation and elongation into longer chained and more unsaturated fatty acids, which
98 are more bioactive than their precursors²². The most common derivative of LA is

99 arachidonic acid (20:4 n-6)^{21,22}. ALA is converted to eicosapentaenoic acid (EPA) (20:5
100 n-3), which is further elongated to docosahexaenoic acid (DHA) (22:6 n-3)²².

101 The conversion of ingested ALA to EPA and DHA within the body is not usually
102 considered to be a reliable source of LC-PUFAs in the human diet. The elongation and
103 desaturation conversions are highly inefficient as most of the fatty acid precursors are
104 utilized for energy²². Furthermore, the conversion yield of ALA to EPA and DHA in
105 men is only 0.3-8% and < 4%, respectively²³. In women, the conversion yield of ALA to
106 EPA and DHA is 21 % and 9%, respectively. This poor production of LC-PUFA in the
107 body makes it more beneficial to consume omega-3 FAs as preformed EPA and DHA,
108 rather than as ALA.

109 2.2. Food sources

110 There are many dietary sources of omega-3 FAs including fish, krill, algae, and land
111 plants⁶. The type and amount of omega-3 FAs varies between sources. Fish is the most
112 common source of omega-3 FAs and the amount of EPA and DHA varies between fish
113 species, time of year, the fish's diet, and geography. Cold water, pelagic fish usually have
114 the highest levels of EPA and DHA. Overall, in marine fish the most important factor is
115 their total fat content, with high fat fish having the highest amount of omega-3s per
116 serving. Sardine, mackerel, herring, and halibut have some of the highest omega-3
117 PUFA levels but are uncommon in many diets⁶. In the United States, salmon, anchovies,
118 herring, sardines, Pacific oysters, trout, and Atlantic and Pacific mackerel are the most
119 commonly consumed low mercury seafood varieties¹¹.

120 The frequent consumption of fish does raise some safety and environmental
121 concerns. Fish is susceptible to bioaccumulation of toxins and pollutants, one of the most
122 common being mercury⁶. An advantage of using fish oils (rather than consuming whole
123 fish) is that oil refining removes the majority of these toxins. Another concern is
124 overfishing of the supply that could strain the sustainability of the market⁸.

125 Alternative marine sources are available as a source of omega-3 FA, without facing
126 some of the challenges associated with using fish. Krill oil can achieve higher levels of
127 EPA and DHA than fish oil but the product has a higher cost so it is usually used in

128 supplements ⁶. In addition, there are non-marine sources of omega-3 FA that can be used
129 commercially in food products. Algae are a primary producers of omega-3 FAs, which
130 can be cultivated to produce a continuous supply of omega-3 FAs. While algae produce
131 high amounts of DHA, the EPA levels are often lower than those found in fish oil ^{22, 24}.
132 Until recently, relatively high production and purification costs limited the large scale
133 manufacturing of algae oils, however, considerable advances have been made in recent
134 years that have led to their increased commercial use ^{22, 24-26}.

135 The Dietary Guidelines and American Dietetic Association encourage nutrient
136 consumption from food rather than supplements however, people may choose to consume
137 supplements or fortified foods for many reasons including cost, their dislike of seafood,
138 allergies, a vegan diet, convenience, and the inability to meet recommended EPA and
139 DHA levels from their normal diet ^{3, 8, 11}. Consumers seeking alternative sources of
140 omega-3 FAs should be aware if the products contain ALA, EPA or DHA in order to
141 receive maximum health benefits.

142 Land plant sources of omega-3 FAs include canola, soy, flaxseed, and walnuts
143 mainly in the form of ALA ^{11, 22, 27}. An increased consumption of omega-3 FAs from
144 these sources may have a limited effect in decreasing cardiovascular disease or a stroke
145 because of the inefficient conversion of ALA to EPA and DHA ²².

146 Supplements may contain EPA and DHA in different forms than the common
147 triglyceride form typically found in fish oil ⁶. Ethyl esters of omega-3 FAs are commonly
148 used in dietary supplements and pharmaceuticals because of ability to be distilled ethyl
149 esters to produce highly concentrated oils ⁶. The ethyl esters of EPA and DHA have a
150 different absorption route in the human body than triglyceride forms, but plasma lipid
151 levels appear to be equivalent, however the triglyceride form can be better utilized in the
152 body ^{6, 28}.

153 **2.3. Fish oil**

154 In the remainder of this section, we will primarily focus on fish oil as it is considered
155 to be the most common, least expensive, and best source of both EPA and DHA in the

156 human diet ²⁷. However, other sources of omega-3 fatty acids are becoming more
157 economically viable, such as genetically engineered oil seeds ^{29, 30}.

158 **2.3.1. Health aspects**

159 Fish oils have been reported to have many mechanisms by which they can reduce
160 cardiovascular disease (CVD) risk factors for morbidity and sudden death. The
161 combined effects of decreased blood pressure, positive shifts in blood lipid profiles (a
162 decrease in LDL cholesterol and increase in HDL cholesterol), lowering of plasma
163 triacylglycerols, improved cell membrane stability (especially in the heart muscles that
164 control heart rate), decreased platelet aggregation, and reduced inflammation contribute
165 to these health benefits ^{27, 31}. Bread rolls, cereal bars and crackers were fortified with
166 DHA and participants consumed the products in order to achieve 2 g of DHA/day. The
167 consistent consumption of DHA increased HDL cholesterol in middle aged men and
168 women and these fortified foods present a convenient way to incorporate omega-3 FAs
169 into the diet ³².

170 The EPA and DHA found in fish oil is also associated with the prevention and
171 possible treatment of inflammatory disease like asthma, cystic fibrosis, and rheumatoid
172 arthritis ^{27, 33}. The anti-inflammatory properties of omega-3 fatty acids may also help
173 patients recover after surgery. Omega-3 FAs administered through a parenteral route to
174 patients after undergoing a liver transplant had positive effects including decreasing the
175 duration of the post-transplant hospital care, reducing infectious morbidities, and
176 protecting the liver from injury partially as a result of the anti-inflammatory effects of the
177 PUFA ³⁴.

178 DHA has been associated with brain development because of the large amounts of
179 DHA in the human nervous system ³³. The cell membranes of the brain and retina of the
180 eye experience a surge of DHA inclusion between the third trimester and the first year
181 after birth ³⁵. Omega-3 FAs are essential for proper brain functioning and development
182 and studies have found connections between maternal consumption of fish and the visual
183 acuity, higher developmental scores at 18 months, and higher IQ of infants ^{33, 35-37}. These
184 preliminary studies highlight the potential importance of DHA consumption for pregnant
185 women.

186 Besides brain development, omega-3 FAs have also been investigated for
187 connections with mental health conditions including attention deficit hyperactivity
188 disorder (ADHD), dyslexia, depression, and adult cognitive decline including dementia
189 and Alzheimer's disease³³. All of these areas require further investigation for various
190 reasons including small sample sizes, inconsistencies in regimes, drug interactions, or
191 conflicting conclusions.

192 **2.3.2. Dietary recommendations for LC-PUFA**

193 Many organizations at the national and international levels have published
194 recommendations for omega-3 FA. These recommendations vary in the specificity of
195 omega-3 FA forms taken, such as fish, ALA, EPA, and DHA, and if subsets of the
196 general population require different recommendations. In the United States, the 2010
197 Dietary Guidelines for Americans suggests consuming 250 mg of EPA and DHA per day
198 through the means of 8 ounces (227 g) of a variety of seafood a week¹¹. It is
199 recommended that pregnant women consume 8 to 12 ounces (227 to 340 g) of low
200 mercury seafood per week¹¹.

201 The *National Academies* (USA) has made its omega-3 FA recommendations using
202 adequate intake values. An adequate intake value is used if a recommended daily
203 allowance cannot be established and is determined based on the intake of healthy people
204³. For males and females 14 years old and above, the adequate intake value of ALA, EPA
205 and DHA are 1.6 and 1.1 g/day, respectively with most of the recommendation coming
206 from ALA³⁸. Pregnant and lactating women have an adequate intake value of 1.4 and
207 1.3 g omega-3s/day, respectively.

208 The American Dietetic Association and Dieticians of Canada recommend 2 servings
209 of fatty fish per week; 8 oz of cooked fish should provide 500 mg of EPA and DHA per
210 day³⁹. The American Diabetes Association suggest at least 2 servings of fish per week
211 for adequate omega-3 FA consumption⁴⁰. Commercially fried fish filets are excluded
212 from this recommendation. The American Heart Association recommends 2 servings of
213 fatty fish per week, a total of 8 oz in order to obtain beneficial amounts of EPA and DHA
214⁴¹.

215 The European Food Safety Agency proposes the dietary intake of 250-500 mg of
216 EPA and DHA/day for adults ^{27,42}. They also acknowledge that supplementing up to 1 g
217 of DHA per day is safe. The Scientific Advisory Committee on Nutrition of Great
218 Britain recommends at least 2 servings of fish (140 g) per week with at least one of the
219 servings from oily fish ². In France, the French National Nutrition and Health Program
220 (PNNS) recommends eating fish two times a week ⁴³. The French Food Safety Agency
221 (AFFSA) recommends that individuals over the age of 10, including pregnant and
222 lactating women, should consume 500 mg of EPA and DHA/day and a minimum of 250
223 mg of DHA/day.

224 The World Health Organization recommends 2 servings of fish per week in order for
225 the consumer to intake about 200 to 500 mg of EPA and DHA per day ⁴⁴. The Australian
226 and New Zealand National Health and Medical Research Council recommends 430 and
227 610 mg/day of DHA/EPA/DPA (docosapentaenoic acid) for women and men between the
228 ages of 19 and 69 years ⁴⁵. For pregnant and lactating women from 19-50 years old, 115
229 and 145 mg/day of DHA/EPA/DPA is recommended.

230 Western diets in general do not provide satisfactory omega-3 FA intakes.
231 American's current consumption of EPA and DHA is lower than the recommended
232 values ^{1,4}. On average, Americans are currently consuming 3.5 ounces (99 g) of seafood
233 per week and much of it is low in omega-3 FAs ^{3,11}. The National Health and Nutrition
234 Examination Survey (NHANES) determined the mean intake of EPA and DHA through
235 food sources by people over 19 years is 23 and 63 mg/day, respectively ^{1,4}. For
236 individuals over the age of 19 consuming EPA and DHA through both food and
237 supplement sources, they are consuming 41 and 72 mg/day, respectively. As of the
238 2008/2009 and 2010/2011 surveys, the actual consumption of oily fish by the population
239 of Great Britain was not meeting the recommendation ^{2,46}. On average, only 54 g of oily
240 fish were consumed per week across the age range of 19-64 years. Adults over 65
241 consumed an average of 90 g of oily fish per week. In contrast, Japanese diets easily
242 provide sufficient omega-3 FA. The Japanese population achieves the recommended
243 intake values of DHA and EPA through their diet high in seafood, and their use of dietary

244 fats high in ALA ⁴⁷. Japanese adults consume about 80 g of fish and shellfish per day,
245 resulting in around 1-2 g of omega-3 FA per day.

246 Although many of the dietary recommendations for omega-3 encourage consumption
247 of fish, this is not always convenient: some people do not like fish; some people cannot
248 afford fish; fresh fish spoils rapidly; fish may contain undesirable contaminants (such as
249 heavy metals); overfishing may reduce the supply of fish available; the growing global
250 population puts a higher demand on the available fish ⁶⁻⁸. Consequently, there is great
251 interest in the development of alternative means of incorporating omega-3 fatty acids into
252 the human diet ⁸.

253 **3. Nanoemulsions**

254 Emulsion-based delivery systems offer a number of potential benefits for introducing
255 omega-3 oils into foods and beverages ⁴⁸⁻⁵⁰. Nanoemulsions are a class of emulsion-
256 based delivery systems that are becoming increasingly popular because of their ease of
257 preparation, small particle size, relatively high stability, and high bioavailability.

258 **3.1. Characteristics of nanoemulsions**

259 Oil-in-water nanoemulsions, which are the most suitable for encapsulating omega-3
260 oils, consist of emulsifier-coated lipid droplets dispersed within an aqueous continuous
261 phase. Nanoemulsions have been defined as emulsions that have mean particle radii
262 below 100 nm ^{18,51}. Unlike microemulsions, which also contain small lipid droplets
263 dispersed in water, nanoemulsions are thermodynamically unstable systems ^{52,53}.
264 Nanoemulsions have been utilized in the food and pharmaceutical industries as delivery
265 systems to encapsulate, protect, and control the release of a variety of bioactives ^{48,49,54}.
266 The small particle size provides both benefits and challenges for nanoemulsions.

267 The bioavailability of lipophilic bioactive components encapsulated in small
268 particles is usually greater than those in larger particles, which may be due to various
269 mechanisms ^{19,54}. Smaller particles have a larger specific surface area allowing for
270 increased enzyme activity at the oil-water interface and therefore faster lipid digestion ¹⁷.
271 ⁵⁴. Smaller particles can also penetrate into the mucus layer coating the epithelium cells

272 of the small intestine, thereby increasing the time for lipid digestion and absorption. In
273 addition, smaller particles may be able to pass through the mucus layer and be absorbed
274 by epithelium cells. Lastly, smaller particle sizes increase the solubility of encapsulated
275 lipophilic components in the aqueous phase close to the particle surfaces due to a
276 curvature effect, thereby increasing the driving force for absorption ^{17, 54}.

277 Nanoemulsions are not thermodynamically stable since the separate oil and water
278 phases have a lower free energy than the emulsified system ^{17, 51}. Nevertheless, they can
279 be designed to have high kinetic stability ⁵⁵. For example, nanoemulsions typically are
280 more resistant to gravitational separation, flocculation, and coalescence than conventional
281 emulsions ¹⁷. Their high stability to gravitational separation can be attributed to two
282 reasons: (i) the creaming or sedimentation velocity is proportional to the square of the
283 particle size; (ii) Brownian motion dominates gravitational forces for small droplets ⁵¹.
284 The high stability of nanoemulsions to droplet aggregation is due to the fact that the
285 attractive forces that normally promote flocculation or coalescence weaken with
286 decreasing droplet size ⁵¹. On the other hand, nanoemulsions are often more susceptible
287 to Ostwald ripening than conventional emulsions. Ostwald ripening in O/W
288 nanoemulsions involves the diffusion of oil phase from small droplets to larger ones
289 resulting in an increase in the mean droplet size ^{17, 51, 56}. Droplet growth due to this
290 mechanism can be inhibited by careful selection of the oil phase or by addition of
291 ripening inhibitors ⁴⁹.

292 Another potential advantage of nanoemulsions for certain applications is that they
293 can appear transparent or only slightly turbid when they are fabricated to have particle
294 sizes much smaller than the wavelength of light (Figure 1) ¹⁸. Typically, the mean
295 droplet radius should be less than about 20-25 nm to ensure high optical clarity of a
296 nanoemulsion, which requires careful control of fabrication conditions and product
297 formulation.

298 **3.2. Fabrication methods**

299 Typically, nanoemulsions require the use of high mechanical energy, high surfactant
300 levels, or both in order to be produced ⁵⁷. In general, nanoemulsion production can be

301 divided into high-energy and low-energy methods⁵⁸. High-energy methods rely on the
302 application of mechanical energy to disrupt the separate oil and water phases, mix the
303 two phases together, and form tiny oil droplets^{49,51}. High-energy methods based on this
304 principle include high pressure valve homogenizers, microfluidizers and sonicators¹⁷.
305 Droplet size is dependent on many variables including the production method, operation
306 settings, and system components¹⁷. Typically, the droplet size decreases with increasing
307 energy input and duration, provided there is sufficient surfactant present and the oil,
308 water, and surfactant type are carefully selected.

309 In contrast, low-energy methods rely on changes in the environment or solution
310 conditions to promote the spontaneous formation of tiny oil droplets⁴⁹. The ability of
311 low-energy methods to produce nanoemulsions are closely related to the physicochemical
312 properties of the surfactant, and depend on the type and amount of surfactant, oil and
313 water present⁵⁵. Low-energy methods for nanoemulsion fabrication are becoming more
314 popular because they can better create smaller particles sizes compared to high energy
315 methods, they have lower manufacturing costs, and they have simple production methods
316⁴⁹.

317 A number of low-energy emulsification methods are available, including the
318 spontaneous emulsification (SE), phase inversion temperature (PIT), phase inversion
319 composition (PIC), and emulsion inversion point (EIP) methods¹⁷. SE uses simple
320 mixing as one phase is slowly added to another to spontaneously form an emulsion, *e.g.*,
321 an organic phase containing surfactant and oil is added to an aqueous phase containing
322 water⁵⁹. The final emulsion can be manipulated by controlling many variables including
323 which phase is added into the other, the composition of the phases, environmental factors
324 (*i.e.* temperature and pH), and mixing conditions (*i.e.* stir speed and rate of addition)⁴⁹.
325 The PIT method utilizes alterations in temperature to change the solubility or optimum
326 curvature (molecular geometry) of non-ionic surfactants, which results in the conversion
327 of an oil-in-water to a water-in-oil emulsion or *vice versa*^{17,59,60}. Typically, a surfactant-
328 oil-water mixture of appropriate composition is heated above the PIT, and then rapidly
329 cooled with continuous stirring to form a nanoemulsion. The PIC method is similar to
330 the PIT method as it relies again on a change in the solubility or optimum curvature of

331 the surfactant, however instead of changing the temperature of the system, the
332 formulation of the system is altered, *e.g.*, salt concentration⁵⁹. Both the PIT and PIC
333 methods rely on a transitional-phase inversion which utilizes the change in surfactant's
334 functional characteristics⁴⁹. The EIP method however relies on catastrophic-phase
335 inversion instead of transitional-phase inversion methods. Catastrophic-phase inversion
336 changes the ratio between the oil and water phases while maintaining the surfactant's
337 properties⁴⁹. This may occur by preparing a water-in-oil emulsion and then adding water
338 while stirring. The water will initially form more droplets in the oil however when
339 excess water is added, the water becomes the continuous phase and the oil becomes
340 droplets leading to the formation of an oil-in-water emulsion.

341 **3.3. Formulating safe nanoemulsions**

342 When formulating nanoemulsions for food systems, food safety is one of the greatest
343 concerns¹⁹, followed by the consumer's desire for clean labels on their foods⁶¹.
344 Reducing the particle size into the nano-range ($r < 100$ nm) may substantially change the
345 gastrointestinal fate of ingested foods, which has led to some concern about the presence
346 of engineered nanoparticles in foods¹⁹. As mentioned earlier, there may be a
347 considerable increase in the oral bioavailability of encapsulated bioactive agents when
348 they are incorporated into nanoemulsions. In many cases, this increase may be desirable,
349 but in some cases it may be undesirable. For example, a bioactive agent may have an
350 optimum blood level concentration for efficacy, but may become toxic at higher levels.
351 If a nanoemulsion greatly increased the concentration of this type of bioactive agent, it
352 may lead to high blood levels that increase toxicity. However, this should not be a
353 problem with omega-3 oils because they can usually be consumed at high levels without
354 causing health problems. Nevertheless, if the oil is highly oxidized then it may contain
355 toxic reaction products that would cause a problem, although consumers usually reject
356 this type of product due to poor sensory characteristics.

357 The presence of certain components in nanoemulsions may also cause concern,
358 particularly high levels of surfactants or solvents. Surfactants are commonly used to
359 stabilize nanoemulsions by adsorbing to droplet surface and protecting them from
360 aggregation⁴⁸. Large amounts of surfactant are typically needed to fabricate

361 nanoemulsions using low-energy methods (such as the spontaneous emulsification or
362 phase inversion temperature methods), but this is less of a problem with the high-energy
363 methods commonly used in the food industry (such as high pressure homogenization or
364 sonication)^{62, 63}. In addition, the surfactants used to form nanoemulsions are typically
365 small molecule synthetic surfactants (such as Tweens), although some progress has been
366 achieved forming nanoemulsions using natural surfactants such as phospholipids or
367 saponins^{64, 65}. There are some health concerns associated with using high amounts of
368 certain types of synthetic surfactants in foods, and so their use is limited by government
369 regulations⁶⁶. Natural biopolymer-based emulsifiers, such as polysaccharides and
370 proteins, cannot currently be used to form nanoemulsions by low-energy fabrication
371 methods⁴⁹, although they can be used to form nanoemulsions by high-energy methods⁶⁷.
372 Toxicity may also arise from the utilization of organic solvents in certain solvent
373 displacement or evaporation methods used to prepare nanoemulsions⁴⁹. Small traces of
374 these solvents may remain in the emulsion and must be monitored. However, most of the
375 fabrication methods currently used to create food emulsions do not require the utilization
376 of organic solvents. Another important issue affecting the potential toxicity of
377 nanoemulsions is the fact that lipid nanoparticles may behave differently in the human
378 body than the larger particles conventionally used in foods, *e.g.*, the location, rate, and
379 extent of absorption¹⁹.

380 **3.4. Formulating label-friendly nanoemulsions**

381 Consumers are increasingly demanding products that are perceived to have “clean
382 labels”^{64, 68}. Changing to natural surfactants may be one way to meet these demands.
383 One natural surfactant that has been investigated is extracted from the bark of the
384 *Quillaja saponin* Molina tree and is marketed commercially as Q-Naturale® (Ingredion,
385 New Jersey). This surfactant has been compared to Tween 80, a common nonionic
386 surfactant used in the food industry, to form nanoemulsions by a high-energy method
387 (microfluidization) using medium chain triglycerides as the oil phase⁶⁴. Q-Naturale
388 exhibited effective surfactant properties, as it was able to form stable nanoemulsions
389 under certain circumstances at relatively low surfactant-to-oil ratios (1:10). The use of
390 clean label ingredients also extends to any cosolvents or antioxidants that are added to the

391 emulsion formulation to increase physical and chemical stability, which may narrow the
392 formulation possibilities for omega-3 nanoemulsions.

393 **4. Applications of nanoemulsions in foods and beverages**

394 The most widely used delivery systems for incorporating omega-3 oils into foods
395 and beverages are bulk oils, emulsions, and powders⁶⁹. These powders are typically
396 formed by spray drying emulsions. Microencapsulation has proved to be a popular way
397 of creating powdered omega-3 that can be incorporated into a variety of food products
398 including baked goods, spreads, and fruit beverages⁷⁰. However, this technology
399 typically only delivers relatively small levels of bioactive lipids since powders usually
400 only contain around 1 to 30% omega-3 FAs¹⁶. Microencapsulated emulsions for food
401 applications have previously been discussed in detail elsewhere and will therefore not be
402 reviewed further here^{16, 70}.

403 Nanoemulsions offer a convenient means of fortifying many aqueous-based food and
404 beverage products with omega-3 oils. Fortified nanoemulsions could be introduced into
405 food systems such as beverages, salad dressings, sauces, dips, and desserts^{71, 72}. Current
406 liquid or semisolid food products that have been enriched with omega-3 FAs using
407 emulsion-based delivery systems include table spreads, yogurts, and milk⁷³⁻⁷⁶. None of
408 these products requires the delivery system to be optically transparent, and therefore
409 emulsions or nanoemulsions could be used, although there may be some advantages in
410 terms of long-term stability and bioavailability from using nanoemulsions⁷⁷. The optical
411 transparency that can be achieved with nanoemulsions allows their application within
412 clear food and beverage products, which would expand the functional food market for
413 lipophilic bioactives. Low-energy fabrication methods are also becoming a larger area of
414 interest because of their beneficial characteristics mentioned previously, *e.g.*, simplicity,
415 low cost, and gentle processing conditions^{59, 72}. That being said, nanoemulsions must be
416 carefully formulated to create physically and chemically stable systems suitable for food
417 applications.

418 5. Obstacles to incorporating Omega-3 nanoemulsions in foods

419 A number of obstacles must be overcome before omega-3 fortified nanoemulsions
420 can be successfully incorporated into commercial food products⁴⁸, such as their
421 susceptibility to lipid oxidation, ensuring the physical stability of the system, delivering a
422 nutritionally beneficial quantity of bioactive in a bioavailable form, and providing a
423 palatable product that is acceptable to consumers. A number of these challenges are
424 discussed in more detail in the remainder of this section.

425 5.1. Oxidation

426 Lipid oxidation in food products causes multiple problems that impact shelf-life,
427 safety, nutritional value, functionality, and flavor^{78,79}. Oxidation is readily noticed by
428 consumers because the products of the reaction cause undesirable sensory attributes in
429 food products at very low levels⁴⁸. Oxidation is the reaction of unsaturated fatty acids
430 (FAs) free radicals and oxygen (**Figure 2**) and occurs in three stages: initiation/induction,
431 propagation, and termination^{78,80,81}. The most common mechanism for oxidation in
432 emulsions is the reaction of free radicals with unsaturated lipids leading to the formation
433 of lipid radicals. These lipid radicals react with oxygen and other lipids, thus beginning
434 the chain reaction (propagation) stage of lipid oxidation⁸⁰. Before oxidation occurs,
435 there is a lag phase, which is the phase that food processors attempt to extend through
436 means of storage in cooler temperatures, decreased oxygen exposure, and addition of
437 antioxidants⁸¹. Once the initiation phase has begun, the rate of oxidation increases
438 exponentially and the food is spoiled.

439 Lipid oxidation is promoted by exposure of unsaturated lipids to air, light, heat, and
440 irradiation⁷⁸. Many factors contribute to an emulsion-based delivery systems
441 susceptibility to oxidation including the composition, structure and organization of the
442 oil, water and interfacial phases, as well as the type, amount, and location of any
443 antioxidants present⁸². Fish oil nanoemulsions are particularly susceptible to lipid
444 oxidation for a number of reasons: high degree of lipid unsaturation; high surface area of
445 exposed lipids; greater light penetration⁸². Indeed, experimental studies have shown that
446 lipid oxidation is faster in protein-stabilized nanoemulsions than in conventional
447 emulsions with similar compositions, which was attributed to the higher lipid surface area

448 ⁸³. Consequently, it may be necessary to take additional steps to stabilize omega-3 oils
449 encapsulated within nanoemulsions when compared to conventional emulsions.

450 Oxidation in nanoemulsions can be partially managed by controlling their
451 physicochemical characteristics. Surfactants can influence the droplet charge, thickness,
452 and permeability, all of which control the ability of pro-oxidants, free radicals, and
453 oxygen to interact with the lipids in the droplets ^{82, 84}. Several studies have shown that
454 anionic surfactants attract cationic transition metals while cationic surfactants repulse
455 them thereby decreasing the rate of oxidation ^{82, 85-88}. In addition, the interfacial layer of
456 an emulsion can form a physical (steric) barrier against the aqueous phase of a system
457 that contains pro-oxidants ^{82, 88}. Thicker interfacial layers offer more protection, which
458 depends on the dimensions and composition of the surfactant's head and tail group. A
459 surfactant with a larger head group (Brij 700) was found to be better at slowing lipid
460 oxidation in salmon oil-in-water emulsions than one with a smaller head group (Brij 76)
461 (Figure 3) ⁸⁸. Conversely, surfactant tail length has been shown to have only a minor
462 impact on oxidative stability ⁸⁹.

463 To prevent oxidation in food systems, radical scavenging and metal chelation are the
464 main antioxidant strategies ^{78, 82, 90}. Free radical scavengers react with free radicals
465 before they can react with unsaturated FAs, and their effectiveness depends on their
466 ability to donate a hydrogen atom to the free radical ⁹¹. Flavonoids tend to be effective
467 free radical scavengers by donating a hydrogen from their hydroxyl groups, however
468 their ability to act as an antioxidant depends on their volatility, pH sensitivity, and
469 polarity. Metal chelation is a mechanism by which an antioxidant reduces the reactivity
470 of the transition metal or physically blocks it from interacting with the lipid ⁸². Metal
471 chelators in oil-in-water emulsions have been shown to promote the movement of iron
472 out of the lipid phase and to remove it from the surface of oil droplets, thereby inhibiting
473 lipid oxidation ^{86, 92, 93}. Studies of the chemical degradation of β -carotene in
474 nanoemulsions (another polyunsaturated bioactive lipid) have shown that the rate of
475 oxidation depends on system conditions (such as pH, ionic strength, temperature, droplet
476 size, and emulsifier type) and can be inhibited by adding appropriate antioxidants ⁹⁴⁻⁹⁷.
477 The addition of antioxidants has also been found to improve the stability of citral oil in

478 nanoemulsions ⁹⁸. Similar factors are likely to affect the rate of omega-3 oxidation in
479 nanoemulsions.

480 Flavonoids can act as antioxidants through the means of radical and oxygen
481 scavenging and have been found to be successful in inhibiting oxidation in fish oil
482 emulsions ⁹⁹. Two Flavonoids from apples (phloretin and phloridzin) have been tested for
483 their ability to inhibit oxidation of PUFA methyl esters in oil-in-water emulsions ¹⁰⁰.
484 Both of these natural components had a significant effect in preventing lipid oxidation,
485 with phloretin having a higher antioxidant activity than phloridzin, which was attributed
486 to the fact that it was more lipophilic and therefore tended to accumulate within the lipid
487 droplets where oxidation occurs. Certain flavanols (quercetin glucosides) have also
488 been evaluated for their antioxidant activity in bulk fish oil and in fish oil-in-water
489 emulsions, and compared with butylated hydroxytoluen (BHT) and alpha-tocopherol ¹⁰¹.
490 The emulsions were formed with methyl linolenate or DHA as the lipid phase. In oil-in-
491 water emulsions, the flavanols were less effective than BHT but more effective than
492 alpha-tocopherol in preventing oxidation. In addition, the flavanols were more effective
493 than both BHT and alpha-tocopherol in the bulk oil oxidation prevention.

494 **5.2. Physical stability**

495 The physical stability of nanoemulsions impacts their shelf life, appearance,
496 functionality, and acceptability to consumers. As previously mentioned, nanoemulsions
497 are most susceptible to Ostwald ripening, which is driven by the degree of water-
498 solubility of the oil phase in the aqueous phase ^{49, 102}. Oils with a higher water-solubility
499 are more susceptible to Ostwald ripening because it is easier for them to migrate through
500 the aqueous continuous phase. Oils with a lower degree of water-solubility, like long
501 chain triglycerides, rarely experience Ostwald ripening. Fish oils contain long chain
502 triglycerides, which makes them resistant to droplet growth due to Ostwald ripening ¹⁰³.
503 If nanoemulsion-based delivery system are formulated using more water-soluble oils
504 (such as flavor oils to mask off flavors), then it may be necessary to carefully design
505 them to avoid Ostwald ripening. For example it may be necessary to mix a certain
506 amount of water-insoluble oil (such as fish, flaxseed, or algae oil) with a flavor oil to
507 prevent droplet growth ⁴⁹. In this case, the water-insoluble oil acts as a ripening inhibitor.

508 The surfactant type and concentration used to create a nanoemulsion or emulsions
509 impacts its susceptibility to flocculation and coalescence^{18, 49, 104}. Non-ionic surfactant-
510 coated and polysaccharide-coated droplets tend to be stable across a wide range of salt
511 and pH conditions because they are mainly stabilized by steric repulsion. On the other
512 hand, phospholipid-coated and protein-coated droplets tend to be highly susceptible to
513 changes in pH and ionic strength because they are mainly stabilized by electrostatic
514 interactions. Non-ionic surfactant stabilized nanoemulsions are influenced by other
515 factors, such as surfactant characteristics and temperature. For example, nanoemulsions
516 formed by spontaneous emulsification experienced coalescence during one month storage
517 when using surfactants with intermediate hydrophilic/lipophilic balance (HLB) numbers
518 (5-9). These surfactants tend to be soluble in both oil and water and form lamellar
519 structures instead of micelles due to their optimum curvature, which do not stabilize
520 nanoemulsions very effectively⁷². Non-ionic surfactant stabilized nanoemulsions may
521 also coalesce upon heating due to changes in the optimum curvature of the surfactant
522 monolayer at elevated temperatures, *i.e.*, dehydration of the head group^{62, 105}.

523 Protein-coated lipid droplets are highly susceptible to flocculation at high salt levels
524 or at pH values close to their isoelectric point (pI) due to a reduction in electrostatic
525 repulsion between the droplets^{106, 107}. Protein-stabilized nanoemulsions should therefore
526 only be used under conditions that favor a strong electrostatic repulsion between the
527 droplets, *i.e.*, low ionic strength and/or pH far from pI. Alternatively, they should be
528 incorporated into products that are highly viscous or gel-like, since then even if
529 aggregation does occur the nanoparticles will not separate from the product due to
530 gravitational separation.

531 **5.3. Reaching the RDA**

532 For a product to be considered to be a functional food, it must provide health benefits
533 exceeding those of basic nutrition¹³. The incorporation of fish oil in foods and beverages
534 meets this definition based on the potential health benefits previously mentioned.
535 However, it is important that the amount of omega-3 FAs present in a functional food is
536 large enough to demonstrate a beneficial health effect¹⁰⁸. Thus products should be
537 fortified with an amount of fish oil that is a substantial amount of the recommended

538 intake value if not the total amount. The total amount of omega-3 fatty acids in a
539 functional food product (m_{w-3}) depends on the fraction of omega-3 fatty acids in the oil
540 phase (Φ_{w-3}), the fraction of oil phase in a nanoemulsion-based delivery system (Φ_{nE}), the
541 amount of nanoemulsion added to the food product (Φ_P), and the serving size of the
542 product (m_P):

$$543 \quad m_{w-3} = m_P \times \Phi_{w-3} \times \Phi_{nE} \times \Phi_P$$

544 For example, for a fish oil containing 50% omega-3 fatty acids ($\Phi_{w-3} = 0.5$), that is
545 converted into a 20 wt% oil-in-water nanoemulsion ($\Phi_{nE} = 0.2$), that is added to a food
546 product that has a serving size of 280 g at a level of 10 wt% ($\Phi_P = 0.1$), then the final
547 amount of omega-3 oil present is 2.8 g (2,800 mg). As mentioned earlier, the
548 recommended intake values of omega-3 fatty acids are around 250 to 1000 mg per day,
549 and therefore this amount should be achievable. The amount of nanoemulsion added to a
550 food product may be limited by changes in optical properties if the nanoemulsion is not
551 completely transparent. Typically, the smaller the droplet size, the more transparent is
552 the nanoemulsion and therefore the more that can be incorporated before the system
553 becomes turbid. It is also important to ensure that the droplets do not grow after the food
554 product has been manufactured, or this could result in an increase in turbidity during
555 storage.

556 **5.4. Bioavailability**

557 With the growing use of emulsion-based delivery systems for human consumption, it
558 is important to evaluate the gastrointestinal fate of the systems to ensure that there are no
559 adverse health effects, and that the bioactive being delivered is indeed being absorbed
560 into the body^{19,109}. *In vitro* and *in vivo* digestion models have become instrumental in
561 undertaking this kind of evaluation¹¹⁰⁻¹¹². Bioaccessibility is an important marker used
562 in these studies that describes the fraction of an ingested compound (the bioactive) that is
563 transferred into a mixed micelle after lipid digestion¹¹³.

564 An ingested nanoemulsion will pass through the mouth and stomach before reaching
565 the small intestine where lipid absorption normally occurs^{114,115}. The size, composition,
566 and surface characteristics of the lipid droplets within a nanoemulsion may change

567 appreciably when they are exposed to gastrointestinal conditions ¹⁹. Upon entering the
568 small intestine, lipase adsorbs to the surfaces of emulsified fats and converts
569 triacylglycerols into monoacylglycerols and free fatty acids (FFA) ²¹. These fatty acids
570 are then incorporated into mixed micelles, travel through the mucus layer, and are
571 absorbed by epithelium cells. The bioavailability of encapsulated fatty acids may be
572 inhibited if the ability of the lipase to adsorb to the surface of lipid droplets and hydrolyze
573 the triglycerides is prevented. The type and amounts of surfactants in a nanoemulsion
574 may therefore impact the rate and extent of lipid digestion and FFA release. For
575 example, corn oil nanoemulsions made using high-energy methods experienced a lag
576 period before FFA release that ranged from 5 to 20 minutes as the mean droplet radius
577 increased ¹¹⁶. This was a result of the lipase not being able to adsorb to the surface of the
578 droplets due to the presence of excess surfactant that competed for the droplet surfaces.
579 In these emulsion, 61-71% of the FFAs were released with higher amounts of FFA being
580 release as the particle radius decreased. The obstruction of lipase as a result of high
581 surfactant concentrations was also seen in medium chain triglyceride nanoemulsions
582 containing vitamin E acetate made from both high and low energy methods ¹¹⁷. In this
583 study, both the high and low energy emulsions had comparable particles sizes and similar
584 behaviors throughout the *in vitro* digestion and both released similar amounts of FFA.

585 Surfactants can also impact the rate of lipid digestion based on their molecular and
586 physicochemical characteristics. A study by Speranza et al. evaluated the effect of
587 nonionic and anionic surfactants with a range of HLB numbers on the bioaccessibility of
588 lipids (trioctanoyl glycerol) in emulsions using an *in vitro* digestion model ¹¹⁸. The
589 results showed that an increasing (HLB) number increased the lag time in the jejunum
590 and decreased the rate of lipolysis. In contrast, increasing the length of the aliphatic
591 chain decreased the lag time in the jejunum, but increased the rate of lipolysis in the
592 small intestine.

593 After FFA and bioactives are liberated from the lipid droplets, they form mixed
594 micelles that travel through the mucus layer, and are then absorbed by the intestinal
595 epithelial cells. When conventional fish oil emulsions were compared with fish oil
596 nanoemulsions, the nanoemulsions had a significantly higher percentage of lipid

597 absorbed compared to the conventional emulsions, which was attributed to their smaller
598 particle size (**Figure 4**)¹¹⁹. A recent study showed that the bioaccessibility of an oil-
599 soluble bioactive component (vitamin E acetate) was higher in nanoemulsions prepared
600 using a low-energy method (EPI) than in those prepared using a high-energy method
601 (microfluidization)¹¹⁷. It was suggested that the high levels of surfactant used in the low-
602 energy method may have increased the amount of bioactive incorporated into the mixed
603 micelles. The surfactant characteristics can also impact FFA absorption¹¹⁸. An
604 increasing surfactant HLB has been reported to increase the bioaccessibility of FFAs in
605 the small intestine.

606 Lastly, the absorption of fish oils from ingested foods is important when developing
607 functional food systems. Researchers investigated the absorption of fish oil in capsules
608 *versus* microencapsulated fish oil incorporated into a milk shake¹²⁰. Both treatments
609 resulted in similar increases of EPA and DHA in blood plasma. Another study looked at
610 yogurt as a carrier product for algal oil nanoemulsions (mean droplet size 258 nm) *versus*
611 bulk oil⁷⁴. In this study, both the nanoemulsion and bulk oil increased DHA levels in
612 blood lipids however; the DHA from the nanoemulsion was more bioavailable than the
613 bulk oil during the first four hours of digestion (**Figure 5**). Both of these studies support
614 the use of microencapsulated or emulsified fish oil in food products and provide an
615 alternative way for consumers to supplement their EPA and DHA intake without
616 swallowing a large pill. The properties of a food system that accompanies the fish oil
617 also has importance. When supplements were consumed with a higher fat meal
618 compared to a lower fat meal, more long chain omega-3 PUFA were available, possibly
619 due to the higher fat content stimulating more digestive enzymes and more mixed
620 micelles²⁸. This again supports the use of functional foods to incorporate omega-3 FA
621 and increase the absorption of the fats as an alternative to supplements.

622 5.5. Flavor

623 As previously mentioned, some consumers must find alternative sources of omega-3
624 FAs because they do not like the flavor or texture of fish or seafood. High quality refined
625 fish oils have little to no flavor. This is unlike oils used in some dietary supplement that
626 are low quality and have strong fishy flavors. Some consumers avoid soft gel capsules of

627 fish oil supplements because of the reflux of fish oil resulting in “fish burps”¹²¹. This is
628 caused by the formation of a layer of the fish oil on top of the stomach contents because
629 the oils have a lower density than the gastric juices. By using a fish oil nanoemulsions
630 incorporated into food products, consumers can receive the benefits of EPA and DHA in
631 a form other than seafood. In addition, nanoemulsions can be designed to be resistant to
632 coalescence and creaming within gastric environments by selecting appropriate
633 emulsifiers so that the oil will not form a layer of oil on the top of the stomach contents
634 and cause reflux issues¹²²⁻¹²⁴. When functional foods are concerned, consumers will not
635 sacrifice the taste of a product, even if the consumer is aware of the potential health
636 benefits of the functional food¹²⁵.

637 **5.6. Consumer acceptance**

638 Studies disagree about which types of food a bioactive component, such as omega-3
639 oils, should be added for maximum consumer interest. In a study by Ares and Gámbaro
640 consumers were more accepting of a functional food when the carrier food was perceived
641 as being healthy¹²⁶. In a separate study by Bech-Larsen and Grunert, it was concluded
642 that functional foods with a healthier base food were perceived as healthier compared to
643 functional foods with an unhealthy base food, however this study also stated that
644 consumers rationalized the enrichment of less healthy foods better than that of already
645 healthy foods¹²⁷. Some consumers have concerns about unhealthy foods that have been
646 fortified because they may now be perceived as a health food by others when in fact
647 they are not¹²⁸.

648 Regardless of the carrier product, it is important to the consumer that the bioactive
649 ingredient and base food are compatible; this is a stronger driving force for the
650 purchasing of functional food products compared to health benefits and attitude towards
651 functional foods¹²⁹. For example, products where fish oil appears to be a more natural fit
652 such as fish balls, rye bread, and tuna salad were expected to receive more positive
653 attention by consumers¹²⁸. Another characteristic of fish oil enriched foods that should
654 be considered when choosing an appropriate food carrier and in the product formulation
655 is the sweetness profile. Participants in a study evaluating the acceptance of fish oil
656 fortified foods were put off by sweet products such as yogurt drinks and sports bars

657 having the addition of fish oil ¹²⁸. In a separate study, women between the ages of 40 and
658 60 years did not accept the addition of sweeteners into a functional food and would rather
659 consume a more natural product ¹²⁵.

660 It is suggested that the use of health claims on functional food labels will have a
661 positive impact on the consumer's view of the healthfulness of that food ¹²⁷. The source
662 of omega-3 fatty acids used in the fortification of foods can affect the cost of the products
663 but also their health benefits. ALA omega-3s may give a cleaner label because they are
664 from plant sources along with a lower price for consumers however, the conversion of
665 ALA to LC-PUFA is quite low, decreasing its actual health benefits ²². The FDA health
666 claim for EPA and DHA containing foods can aid in the marketing and advertising for
667 qualifying products while differentiating them from products that only provide ALA.

668 Finally, sensory aspects also play a key role in consumer acceptance of foods. Few
669 studies have researched the effect of nanoemulsions on the sensory properties of enriched
670 foods. Dairy products have been the main focus of these studies. One study evaluated
671 the fishy off flavor intensity of strawberry yogurt containing emulsified omega-3 oils
672 after 14 days storage ⁷³. This study found no significant difference between the control
673 and fortified yogurt samples amongst an untrained consumer panel. Another study
674 evaluated a strawberry drinking yogurt fortified with bulk algae oil and algae oil
675 nanoemulsion for smell, appearance, flavor, texture, consistency, aftertaste, and overall
676 acceptability ¹³⁰. Consumers were able to identify a sensory difference between yogurts
677 fortified with either bulk oil or nanoemulsions in a triangular test. However, no
678 statistically significant differences were found between the nanoemulsion-fortified, bulk
679 oil-fortified, and unfortified yogurts in terms of their consistency and appearance. The
680 sensory properties of cheese fortified with bulk fish oil or fish oil nanoemulsion have also
681 been evaluated ¹³¹. Fishy off flavor was dependent on the concentration of fish oil in the
682 sample and was more easily detected in the bulk oil-fortified samples compared to the
683 nanoemulsion-fortified samples. Clearly, more research should be conducted to evaluate
684 the sensory aspects of foods fortified with nanoemulsions to better understand their effect
685 on consumer acceptance.

686 **6. Conclusions**

687 The low consumption of omega-3 FAs in Western diets clearly shows the need for
688 alternative food sources on the market that provide these essential fatty acids. Fish oil is
689 an effective functional food ingredient because it is a good source of both EPA and DHA.
690 Consumers will be more likely to buy functional foods with fish oil if the carrier food is
691 compatible with the fat and if the foods are more savory instead of sweet. Whether the
692 fish oil should be added to healthy or unhealthy foods is debated and should be evaluated
693 on a product-by-product basis. Nanoemulsions are a promising way to deliver fish oils
694 into liquid food systems with the capabilities to protect the oil from oxidation, mask
695 undesirable off-flavors, and increase oral bioavailability. Most importantly, the ability of
696 nanoemulsions to be added to clear products increases the range of products that omega-3
697 FA enrichment can be applied to. That being said, there is still a need to expand omega-3
698 nanoemulsion research in order to optimize the fabrication method and formulation as a
699 way to increase palatability, shelf life, and other physical characteristics of the food
700 product.

701 **7. Acknowledgements**

702 This material is based upon work supported by the Cooperative State Research,
703 Extension, Education Service, United State Department of Agriculture, Massachusetts
704 Agricultural Experiment Station and United States Department of Agriculture, NIFA
705 Grant and a USDA/EPA/NSF grant (**2011-03539 and 2013-03795**).

706

707 **8. References**

- 708 1. Center for Disease Control and Protections, National Center for Health Statistics,
709 2003.
- 710 2. Great Britain Scientific Advisory Committee on Nutrition, *The nutritional*
711 *wellbeing of the British population*, The Stationary Office, Norwich, 2008.
- 712 3. P. M. Kris-Etherton, J. A. Grieger and T. D. Etherton, *Prostaglandins,*
713 *Leukotrienes and Essential Fatty Acids*, 2009, **81**, 99-104.
- 714 4. Y. Papanikolaou, J. Brooks, C. Reider and V. L. Fulgoni, *Nutrition Journal*, 2014,
715 **13**.
- 716 5. G. Danaei, E. L. Ding, D. Mozaffarian, B. Taylor, J. Rehm, C. J. L. Murray and
717 M. Ezzati, *PLoS Medicine*, 2009, **6**, 1-23.
- 718 6. R. A. Racine and R. J. Deckelbaum, *Current Opinion in Clinical Nutrition &*
719 *Metabolic Care March 2007*, 2007, **10**, 123-128.
- 720 7. K. Glanz, M. Basil, E. Maibach, J. Goldberg and D. A. N. Snyder, *Journal of the*
721 *American Dietetic Association*, 1998, **98**, 1118-1126.
- 722 8. E. T. Kennedy, H. Luo and L. M. Ausman, *J. Nutr.*, 2012, **142**, 605S-609S.
- 723 9. P. J. Gillies, W. S. Harris and P. M. Kris-Etherton, *Current Atherosclerosis*
724 *Reports*, 2011, **13**, 467-473.
- 725 10. Center for Food Safety and Applied Nutrition, 2013.
- 726 11. U. S. Department of Agriculture and U. S. Department of Health and Human
727 Services, U.S. Government Printing Office, Washington DC, 7th edn., 2010.
- 728 12. U. S. Department of Agriculture and U. S. Department of Health and Human
729 Services, USDA, 2010.
- 730 13. C. Hasler, A. Bloch and C. Thomson, *Journal of the American Dietetic*
731 *Association*, 2004, **104**, 814-826.
- 732 14. E. Hudson, *Nutraceutical Business & Technology*, 2010, **6**, 30-32.
- 733 15. I. Fraeye, C. Bruneel, C. Lemahieu, J. Buyse, K. Muylaert and I. Foubert, *Food*
734 *Research International*, 2012, **48**, 961-969.
- 735 16. M. L. Garg, L. G. Wood, H. Singh and P. J. Moughan, *J Food Sci*, 2006, **71**, R66-
736 R71.
- 737 17. D. J. McClements, *Soft Matter*, 2011, **7**, 2297-2316.
- 738 18. T. G. Mason, J. N. Wilking, K. Meleson, C. B. Chang and S. M. Graves, *J. Phys.:*
739 *Condens. Matter*, 2006, **18**.
- 740 19. D. J. McClements, *Progress in Lipid Research*, 2013, **52**, 409-423.
- 741 20. M. F. Yao, H. Xiao and D. J. McClements, *Annual Review of Food Science and*
742 *Technology, Vol 5*, 2014, **5**, 53-81.
- 743 21. S. A. S. Gropper, J. L. Smith and J. L. Groff, *Advanced nutrition and human*
744 *metabolism*, Wadsworth Cengage Learning, 2009.
- 745 22. R. J. Deckelbaum and C. Torrejon, *J. Nutr.*, 2012, **142**, 587S-591S.
- 746 23. L. M. Arterburn, E. B. Hall and H. Oken, *Am J Clin Nutr*, 2006, **83**, S1467-
747 1476S.
- 748 24. K. C. Maki, K. Yurko-Mauro, M. R. Dicklin, A. L. Schild and J. G. Geohas,
749 *Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA)*, 2014, **91**, 141-
750 148.

- 751 25. T. C. Adarme-Vega, D. K. Y. Lim, M. Timmins, F. Vernen, Y. Li and P. M.
752 Schenk, *Microbial Cell Factories*, 2012, **11**.
- 753 26. G. Lenihan-Geels, K. Bishop and L. Ferguson, *Nutrients*, 2013, **5**, 1301-1315.
- 754 27. J. A. Tur, M. M. Bibiloni, A. Sureda and A. Pons, *The British Journal of*
755 *Nutrition*, 2012, **107 Suppl 2**.
- 756 28. J. P. Schuchardt and A. Hahn, *Prostaglandins, Leukotrienes and Essential Fatty*
757 *Acids (PLEFA)*, 2013, **89**, 1-8.
- 758 29. S. M. Kitessa, M. Abeywardena, C. Wijesundera and P. D. Nichols, *Nutrients*,
759 2014, **6**, 2035-2058.
- 760 30. L. Pottel, M. Lycke, T. Boterberg, I. Foubert, H. Pottel, F. Duprez, L. Goethals
761 and P. R. Debruyne, *Phytochemistry Reviews*, 2014, **13**, 223-244.
- 762 31. J. N. Din, S. A. Harding, C. J. Valerio, J. Sarma, K. Lyall, R. A. Riemersma, D.
763 E. Newby and A. D. Flapan, *Atherosclerosis*, 2008, **197**, 290-296.
- 764 32. R. A. Harrison, M. Sagara, A. Rajpura, L. Armitage, N. Birt, C. A. Birt and Y.
765 Yamori, *Nutrition, Metabolism and Cardiovascular Diseases*, 2004, **14**, 344-350.
- 766 33. C. H. S. Ruxton, S. C. Reed, M. J. A. Simpson and K. J. Millington, *Journal of*
767 *Human Nutrition and Dietetics*, 2004, **17**, 449-459.
- 768 34. X.-H. Zhu, *World Journal of Gastroenterology*, 2012, **18**.
- 769 35. M. H. Jorgensen, O. Hernell, E. L. Hughes and K. F. Michaelsen, *Journal of*
770 *Pediatric Gastroenterology*, 2001, **32**, 293-296.
- 771 36. J. L. Daniels, M. P. Longnecker, A. S. Rowland and J. Golding, *Epidemiology*,
772 2004, **15**, 394-402.
- 773 37. I. B. Helland, L. Smith, K. Saarem, O. D. Saugstad and C. A. Drevon, *Pediatrics*,
774 2003, **111**, e39-e44.
- 775 38. National Research Council, *Dietary Reference Intakes for Energy, Carbohydrate,*
776 *Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients)*,
777 National Academies Press, Washington DC, 2005.
- 778 39. P. M. Kris-Etherton and S. Innis, *Journal of the American Dietetic Association*,
779 2007, **107**, 1599-1161.
- 780 40. American Diabetes Association, *Diabetes Care*, 2008, **31**, S61-S78.
- 781 41. A. H. Lichtenstein, L. J. Appel, M. Brands, M. Carnethon, S. Daniels, H. A.
782 Franch, B. Franklin, P. Kris-Etherton, W. S. Harris, B. Howard, N. Karanja, M.
783 Lefevre, L. Rudel, F. Sacks, L. V. Horn, M. Winston and J. Wylie-Rosett,
784 *Arterioscler Thromb Vasc Biol*, 2006, **26**, 2186-2191.
- 785 42. EFSA Panel on Dietetic Products, Nutrition and Allergies, *EFSA Journal*, 2012,
786 **10**, 2815-2863.
- 787 43. French Food Safety Agency (AFFSA), The Director General, 2010.
- 788 44. World Health Organisation and Food and Agriculture Organization, *Diet,*
789 *Nutrition and the Prevention of Chronic Diseases: Report of a Joint WHO/FAO*
790 *Expert Consultation*, World Health Organization (WHO), Geneva, CHE, 2003.
- 791 45. Aurlalia and New Zealand National Health and Medical Research Council,
792 *Nutrient Reference Values for Australia and New Zealand*, 2006.
- 793 46. B. Bates, A. Lennox, A. Prentice, C. Bates, P. Page, S. Nicholson and G. Swan,
794 eds. Public Health England and Food Standards Agency, Public Health England,
795 London, UK, 2014.
- 796 47. M. Sugano and F. Hirahara, *Am J Clin Nutr*, 2000, **71**, 189S-196S.

- 797 48. D. J. McClements, E. A. Decker and J. Weiss, *Journal of Food Science*, 2007, **72**,
798 R109-R124.
- 799 49. D. J. McClements and J. Rao, *Critical Reviews in Food Science and Nutrition*,
800 2011, **51**, 285-330.
- 801 50. X. Li, N. Anton and T. Vandamme, *Nano-Emulsions: Overview and Applications*,
802 2013.
- 803 51. T. Tadros, P. Izquierdo, J. Esquena and C. Solans, *Advances in Colloid and*
804 *Interface Science*, 2004, **108–109**, 303-318.
- 805 52. D. J. McClements, *Soft Matter*, 2012, **8**, 1719-1729.
- 806 53. N. Anton and T. F. Vandamme, *Pharmaceutical Research*, 2011, **28**, 978-985.
- 807 54. E. Acosta, *Current Opinion in Colloid & Interface Science*, 2009, **14**, 3-15.
- 808 55. N. Anton, J.-P. Benoit and P. Saulnier, *Journal of Controlled Release*, 2008, **128**,
809 185-199.
- 810 56. A. Kabalnov, *Journal of Dispersion Science & Technology*, 2001, **22**.
- 811 57. S. M. Jafari, Y. He and B. Bhandari, *European Food Research and Technology =*
812 *Zeitschrift für Lebensmittel-Untersuchung und -Forschung. A*, 2007, **225**, 733-
813 741.
- 814 58. A. Forgiarini, J. Esquena, C. González and C. Solans, *Langmuir*, 2001, **17**, 2076-
815 2083.
- 816 59. N. Anton and T. F. Vandamme, *International Journal of Pharmaceutics*, 2009,
817 **377**, 142-147.
- 818 60. J. M. Gutierrez, C. Gonzalez, A. Maestro, I. Sole, C. M. Pey and J. Nolla, *Curr*
819 *Opin Colloid In*, 2008, **13**, 245-251.
- 820 61. A. E. Sloan, *Food Technology*, 2012, **66**, 1-5.
- 821 62. A. H. Saberli, Y. Fang and D. J. McClements, *Food Research International*, 2013,
822 **54**, 812-820.
- 823 63. F. Ostertag, J. Weiss and D. J. McClements, *Journal of Colloid and Interface*
824 *Science*, 2012, **388**, 95-102.
- 825 64. Y. Yang, M. E. Leser, A. A. Sher and D. J. McClements, *Food Hydrocolloids*,
826 2013, **30**, 589-596.
- 827 65. B. Ozturk, S. Argin, M. Ozilgen and D. J. McClements, *Journal of Food*
828 *Engineering*, 2014, **142**, 57-63.
- 829 66. I. Kralova and J. Sjöblom, *Journal of Dispersion Science & Technology*, 2009,
830 **30**, 1363-1383.
- 831 67. C. Qian and D. J. McClements, *Food Hydrocolloids*, 2011, **25**, 1000-1008.
- 832 68. Ö. Güçlü-Üstündağ and G. Mazza, *Critical Reviews in Food Science and*
833 *Nutrition*, 2007, **47**, 231-258.
- 834 69. C. Jacobsen, *Annals of the New York Academy of Sciences*, 2010, **1190**, 141-150.
- 835 70. S. Drusch, in *Encapsulation Technologies and Delivery Systems for Food*
836 *Ingredients and Nutraceuticals*, ed. N. Garti and D. J. McClements, 2012, pp.
837 488-504.
- 838 71. K. Velikov and E. Pelan, *Soft Matter*, 2008, **4**, 1964-1980.
- 839 72. Y. Yang, C. Marshall-Breton, M. E. Leser, A. A. Sher and D. J. McClements,
840 *Food Hydrocolloids*, 2012, **29**, 398-406.

- 841 73. C. P. Chee, J. J. Gallaher, D. Djordjevic, H. Faraji, D. J. McClements, E. A.
842 Decker, R. Hollender, D. G. Peterson, R. F. Roberts and J. N. Coupland, *Journal*
843 *of Dairy Research*, 2005, **72**, 311-316.
- 844 74. K. E. Lane, W. Li, C. Smith and E. Derbyshire, *Int J Food Sci Technol*, 2014, **49**,
845 1264-1271.
- 846 75. S. P. O' Dwyer, D. O' Beirne, D. Ni Eidhin, A. A. Hennessy and B. T. O'
847 Kennedy, *LWT - Food Science and Technology*, 2013, **51**, 484-491.
- 848 76. R. Sharma, *Australian Journal of Dairy Technology*, 2005, **60**, 195-198.
- 849 77. D. J. McClements and H. Xiao, *Food & Function*, 2012, **3**, 202-220.
- 850 78. E. Arab-Tehrany, M. Jacquot, C. Gaiani, M. Imran, S. Desobry and M. Linder,
851 *Trends in Food Science & Technology*, 2012, **25**, 24-33.
- 852 79. C. D. Dacaranhe and J. Terao, *Journal of Food Science*, 2001, **66**, 422-427.
- 853 80. D. J. McClements and E. A. Decker, *Journal of Food Science*, 2000, **65**, 1270-
854 1282.
- 855 81. D. J. McClements and E. A. Decker, in *Food Chemistry, 4th Edition*, ed. S.
856 Damodaran, K. L. Parkin and F. O.R., CRC Press, Boca Raton, 2008, pp. 155-
857 216.
- 858 82. T. Waraho, D. J. McClements and E. A. Decker, *Trends in Food Science &*
859 *Technology*, 2011, **22**, 3-13.
- 860 83. S. J. Lee, S. J. Choi, Y. Li, E. A. Decker and D. J. McClements, *Journal of*
861 *Agricultural and Food Chemistry*, 2011, **59**, 415-427.
- 862 84. A. Villiere, M. Viau, I. Bronnec, N. Moreau and C. Genot, *Journal of*
863 *Agricultural and Food Chemistry*, 2005, **53**, 1514-1520.
- 864 85. C. S. Boon, Z. Xu, X. Yue, D. J. McClements, J. Weiss and E. A. Decker, *Journal*
865 *of Agricultural and Food Chemistry*, 2008, **56**, 1408-1414.
- 866 86. J. R. Mancuso, D. J. McClements and E. A. Decker, *Journal of Agricultural and*
867 *Food Chemistry*, 1999, **47**, 4112-4116.
- 868 87. J. R. Mancuso, D. J. McClements and E. A. Decker, *Journal of Agricultural and*
869 *Food Chemistry*, 2000, **48**, 213-219.
- 870 88. M. P. C. Silvestre, W. Chaayasit, R. G. Brannan, D. J. McClements and E. A.
871 Decker, *Journal of Agricultural and Food Chemistry*, 2000, **48**, 2057-2061.
- 872 89. W. Chaayasit, M. P. C. Silvestre, D. J. McClements and E. A. Decker, *Journal of*
873 *Agricultural and Food Chemistry*, 2000, **48**, 3077-3080.
- 874 90. N. Belhaj, E. Arab-Tehrany and M. Linder, *Process Biochem.*, 2010, **45**, 187-195.
- 875 91. S. Damodaran, K. L. Parkin and O. R. Fennema, *Fennema's food chemistry*,
876 *fourth edition*, CRC Press, 2008.
- 877 92. Y. J. Cho, J. Alamed, D. J. McClements and E. A. Decker, *Journal of Food*
878 *Science*, 2003, **68**, 1952-1957.
- 879 93. L. Mei, D. J. McClements, J. Wu and E. A. Decker, *Food Chemistry*, 1998, **61**,
880 307-312.
- 881 94. C. Qian, E. A. Decker, H. Xiao and D. J. McClements, *Food Chemistry*, 2012,
882 **135**, 1036-1043.
- 883 95. C. Qian, E. A. Decker, H. Xiao and D. J. McClements, *Food Chemistry*, 2012,
884 **132**, 1221-1229.
- 885 96. J. Yi, Y. Li, F. Zhong and W. Yokoyama, *Food Hydrocolloids*, 2014, **35**, 19-27.

- 886 97. D. X. Xu, X. Y. Wang, J. P. Jiang, F. Yuan, E. A. Decker and Y. X. Gao, *LWT-*
887 *Food Sci. Technol.*, 2013, **54**, 236-241.
- 888 98. Q. Zhao, C. T. Ho and Q. R. Huang, *Journal of Agricultural and Food Chemistry*,
889 2013, **61**, 7462-7469.
- 890 99. C. A. Rice-Evans, N. J. Miller and G. Paganga, *Free Radical Biology and*
891 *Medicine*, 1996, **20**, 933-956.
- 892 100. H. P. Vasantha Rupasinghe and A. Yasmin, *Molecules*, 2010, **15**, 251-257.
- 893 101. G. M. Huber, H. P. Vasantha Rupasinghe and F. Shahidi, *Food Chemistry*, 2009,
894 **117**, 290-295.
- 895 102. T. J. Wooster, M. Golding and P. Sanguansri, *Langmuir*, 2008, **24**, 12758-12765.
- 896 103. A. Gulotta, A. H. Saberi, M. C. Nicoli and D. J. McClements, *Journal of*
897 *Agricultural and Food Chemistry*, 2014, **62**, 1720-1725.
- 898 104. C. Qian, E. A. Decker, H. Xiao and D. J. McClements, *Food Chemistry*, 2012,
899 **135**, 1440-1447.
- 900 105. A. H. Saberi, Y. Fang and D. J. McClements, *Journal of Colloid and Interface*
901 *Science*, 2013, **411**, 105-113.
- 902 106. S. J. Lee and D. J. McClements, *Food Hydrocolloids*, 2010, **24**, 560-569.
- 903 107. E. Troncoso, J. M. Aguilera and D. J. McClements, *Journal of Colloid and*
904 *Interface Science*, 2012, **382**, 110-116.
- 905 108. C. S. Patch, L. C. Tapsell and P. G. Williams, *Journal of Nutrition Education &*
906 *Behavior*, 2005, **37**, 235-241.
- 907 109. H. Bouwmeester, S. Dekkers, M. Y. Noordam, W. I. Hagens, A. S. Bulder, C. de
908 Heer, S. ten Voorde, S. W. P. Wijnhoven, H. J. P. Marvin and A. Sips, *Regulatory*
909 *Toxicology and Pharmacology*, 2009, **53**, 52-62.
- 910 110. D. J. McClements and Y. Li, *Food Funct.*, 2010, **1**, 32-59.
- 911 111. C. J. H. Porter and W. N. Charman, *Advanced Drug Delivery Reviews*, 2001, **50**,
912 S127-S147.
- 913 112. M. Minekus, M. Alminger, P. Alvito, S. Ballance, T. Bohn, C. Bourlieu, F.
914 Carriere, R. Boutrou, M. Corredig, D. Dupont, C. Dufour, L. Egger, M. Golding,
915 S. Karakaya, B. Kirkhus, S. Le Feunteun, U. Lesmes, A. Macierzanka, A. Mackie,
916 S. Marze, D. J. McClements, O. Menard, I. Recio, C. N. Santos, R. P. Singh, G.
917 E. Vegarud, M. S. J. Wickham, W. Weitschies and A. Brodkorb, *Food Funct.*,
918 2014, **5**, 1113-1124.
- 919 113. C. Sy, B. Gleize, O. Dangles, J.-F. Landrier, C. C. Veyrat and P. Borel, *Molecular*
920 *Nutrition & Food Research*, 2012, **56**, 1385-1397.
- 921 114. D. J. McClements, E. A. Decker and Y. Park, *Crit Rev Food Sci*, 2009, **49**, 48-67.
- 922 115. H. Singh, A. Ye and D. Horne, *Progress in Lipid Research*, 2008.
- 923 116. E. Troncoso, J. M. Aguilera and D. J. McClements, *Food Hydrocolloids*, 2012,
924 **27**, 355-363.
- 925 117. S. Mayer, J. Weiss and D. J. McClements, *Journal of Colloid and Interface*
926 *Science*, 2013, **404**, 215-222.
- 927 118. A. Speranza, M. G. Corradini, T. G. Hartman, D. Ribnicky, A. Oren and M. A.
928 Rogers, *Journal of Agricultural and Food Chemistry*, 2013, **61**, 6505-6515.
- 929 119. T. k. Dey, S. Ghosh, M. Ghosh, H. Koley and P. Dhar, *Food Research*
930 *International*, 2012, **49**, 72-79.

- 931 120. P. A. Morrissey, S. Higgins, Y. L. Carroll and N. M. O'Brien, *Journal of Human*
932 *Nutrition & Dietetics*, 1999, **12**, 265-271.
- 933 121. I. J. Haug, L. B. Sagmo, D. Zeiss, I. C. Olsen, K. I. Draget and T. Seternes, *Eur.*
934 *J. Lipid Sci. Technol.*, 2011, **113**, 137-145.
- 935 122. P. J. Wilde and B. S. Chu, *Adv Colloid Interfac*, 2011, **165**, 14-22.
- 936 123. L. Marciani, M. Wickham, G. Singh, D. Bush, B. Pick, E. Cox, A. Fillery-Travis,
937 R. Faulks, C. Marsden, P. A. Gowland and R. C. Spiller, *Gastroenterology*, 2006,
938 **130**, A227-A227.
- 939 124. L. Marciani, M. Wickham, G. Singh, D. Bush, B. Pick, E. Cox, A. Fillery-Travis,
940 R. Faulks, C. Marsden, P. A. Gowland and R. C. Spiller, *American Journal of*
941 *Physiology-Gastrointestinal and Liver Physiology*, 2007, **292**, G1607-G1613.
- 942 125. D. N. Cox, A. Koster and C. G. Russell, *Appetite*, 2004, **43**, 55-64.
- 943 126. G. Ares and A. Gámbaro, *Appetite*, 2007, **49**, 148-158.
- 944 127. T. Bech-Larsen and K. G. Grunert, *Appetite*, 2003, **40**, 9-14.
- 945 128. R. Krutulyte, K. G. Grunert, J. Scholderer, K. S. Hagemann, P. Elgaard, B.
946 Nielsen and J. P. Graverholt, *Appetite*, 2008, **51**, 137-147.
- 947 129. R. Krutulyte, K. G. Grunert, J. Scholderer, L. Lähteenmäki, K. S. Hagemann, P.
948 Elgaard, B. Nielsen and J. P. Graverholt, *Food Quality and Preference*, 2011, **22**,
949 11-16.
- 950 130. K. E. Lane, E. J. Derbyshire, C. J. Smith, K. Mahadevan and W. Li, *Proceedings*
951 *of the Nutrition Society*, 2013, **72**, E99-E99.
- 952 131. A. Ye, J. Cui, A. Taneja, X. Zhu and H. Singh, *Food Research International*,
953 2009, **42**, 1093-1098.
- 954
- 955

Figure 1. A schematic diagram comparing the appearance and particle size of emulsions and nanoemulsions. Nanoemulsions appear transparent because the particle size is smaller than the wavelength of light and so they only scatter light weakly.





Figure 2. Proposed mechanism of lipid oxidation in an oil-in-water emulsion or nanoemulsion.



PUFA: Polysaturated fatty acid ROOH: Lipid hydroperoxide RO·: Alkoyl radiacals L·: lipid radical LOO·: lipid radical

Figure 3. Comparison of lipid peroxide formation in salmon oil nanoemulsions (mean diameter = 200 nm) stabilized by Brij 76 and Brij 700. Samples were stored at pH 7.0 and 32 °C. Graph replotted from Silvestre, et al.⁸⁸.




Figure 4. Comparison of EPA and DHA absorption in the intestinal tract of rats when delivered as nanoemulsions (mean diameter = 82 nm) or conventional emulsions (mean diameter = 1580 nm). Volume percentage of the emulsion absorbed was measured at three time intervals. *Mean values were significantly different ($P < 0.05$). Graph replotted from Dey, et al. ¹¹⁹.




Figure 5. Comparison of the mean baseline adjusted percentage blood fatty acid levels for DHA after subjects consumed algal oil delivered in either nanoemulsions or bulk oil incorporated into yogurt. *Mean values were significantly different ($P < 0.05$). Graph replotted from Lane, et al. ⁷⁴.

